Vitality Biopharma, Inc. announced the resignation of CEO and director Robert Brooke, the appointment of current board member Michael Cavanaugh as Vitality's interim CEO and the promotion of current Controller and Counsel Richard McKilligan to CFO and Counsel. Mr. Brooke, a bioengineer by training, was a co-founder of the Company along with recently-departed director Dr. Avtar Dhillon. Mr. Brooke plans to focus on private biotechnology ventures as well as non-profit patient advocacy and disease research initiatives.

Michael Cavanaugh, Vitality's interim CEO, will continue to focus on building long-term sustainable shareholder value through the Company's prodrug development program and, additionally, expand its mission to explore accretive investment opportunities in the cannabis industry. Mr. Cavanaugh has over twenty years of experience managing, advising and investing in public and private companies, particularly companies in transition. Richard McKilligan has been promoted to Chief Financial Officer and will continue to serve as Counsel and Secretary.

He joined Vitality in April 2012 as Controller, Counsel and Secretary. Mr. McKilligan is also a director of Bristol Investment Fund Ltd. He served as Chief Financial Officer, General Counsel and Secretary of Research Solutions, Inc. from 2007 to 2011 and Chief Compliance Officer and Counsel to Bristol Capital Advisors, LLC from 2006 to 2008.